Address: Werner-von-Siemens-Straße 22-28
64625 Bensheim
Tel: +49 (0) 6251 – 1083-0
Web: http://www.koehler-chemie.de/deutsch/startseite/
Dr. Franz Köhler Chemie, the company, specialises in organ-protecting solutions, therapeutics, x-ray contrast agents and antidotes. On this basis, Dr. Gernot Köhler, from the second generation, has expanded the company into an innovative, research-intensive and high performance pharmaceuticals company in Alsbach, the USA and Russia. Distributing associates represent the company worldwide. Internal research makes innovative products and continuous development possible. As a result, new therapeutic approaches are formulated in close co-operation with qualified doctors and research is carried out effectively and dependent on requirements. “We are at your service” is the mission statement with which we shall continue to contribute to advances in science and medicine in the interests of the user and patients alike.
Dr. Franz Josef Köhler founded the company in 1959. He is the founder of aspartic therapy and a promoter of organ-protecting solutions. In his honour, the German Society for Thoracic and Cardiovascular Surgery has awarded the “Franz J. Köhler Award” every year since 1990, for outstanding work in the field of organ protection with special emphasis on the heart. His son, Dr. Gernot Köhler, has headed this modern medium sized company since 1984, guiding it into new areas of business.
Dr. Franz Köhler Chemie produces at two German locations thereby meeting the increasing international demand for organ-protecting solutions. The products, perfusion, infusion and injection solutions from Alsbach and Bensheim in South Hesse are in a leading position internationally.
Oskar Möbert, vice president of Veeva OpenData, discusses how standardizing customer reference data and systems organization-wide can help biopharmas scale globally and become more agile in their business. Data…
The biggest pharma industry and healthcare stories from Germany, including the country’s legalisation of cannabis; the MASH potential of Boehringer Ingelheim’s obesity candidate; Bayer’s further share price drop and expansion…
Pharma is rushing to adopt AI-driven tools in the hope of revolutionizing everything from drug discovery to clinical trials, regulatory submissions, and marketing efforts. While AI is the technology du…
Susanne Schaffert’s over 20-year stint at Novartis culminated with her presidency of the Swiss giant’s global oncology division, but when the company underwent a major restructure in 2022, she found…
As head of digital transformation at Bayer, Saskia Steinacker is well placed to unpack the hype around artificial intelligence in healthcare. In a wide-ranging interview, she explains how AI is…
Rainer Westermann of venture capitalist coalition Life Sciences Acceleration Alliance reviews the potential impact of the EU’s general pharmaceutical legislation on the investment climate for the EU life sciences sector.…
The latest pharma industry news from Germany, including Lilly’s new German plant; Bayer’s aborted anti-clotting drug trial and legal worries; Boehringer Ingelheim’s acquisition of Swiss biotech T3 Pharmaceuticals, and Hermes…
After positions at Novartis and Merck, Bettina Bauer, a trained scientist, joined Gilead in 2019 as VP and general manager of its German affiliate. Today, as the VP of the…
Merck’s Kaushal Kishore attempts to illustrate why pharma companies have struggled to crack what he calls “the Gross to Net (GtN) code.” He outlines the maturity journey for a pharma…
Patents can be an excellent way to demonstrate value, not only showing that a technology is protected but also how promising it can be when it eventually comes to market.…
The rise of niche therapies is shaping a more tailored engagement model, driven by data and AI, writes Florian Schnappauf, vice president of enterprise commercial strategy at Veeva Europe. …
Following the COVID-19 pandemic and the resulting supply chain disruptions, global drug pricing and access reforms have multiplied. The Inflation Reduction Act (IRA) has been introduced in the US while…
See our Cookie Privacy Policy Here
